cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Amylyx Pharmaceuticals Inc
5 watching
Current Price
$0
$-1.57
(-3.99%)
logo-amlx
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
2,305.62M
52-Week High
52-Week High
41.9297
52-Week Low
52-Week Low
6.51
Average Volume
Average Volume
0.39M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization2,305.62M
icon52-Week High41.9297
icon52-Week Low6.51
iconAverage Volume0.39M
iconDividend Yield--
iconP/E Ratio--
What does the Amylyx Pharmaceuticals Inc do?
Amylyx Pharmaceuticals, Inc., a biopharmaceutical company, develops therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases in the United States and Canada. The company s product candidature includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and tauroursodeoxycholic acid for the treatment of ALS and other neurodegenerative diseases. It is also developing products for Wolfram syndrome and Alzheimer's diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Read More
How much money does Amylyx Pharmaceuticals Inc make?
News & Events about Amylyx Pharmaceuticals Inc.
Business Wire
16days ago
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) (Amylyx or the Company) today announced it has entered into an exclusive license and distribution agreement with Neopharm in which Neopharm will commercialize, subject to regulatory review and approval, AMX0035 (sodium phenylbutyrate and...
Ticker Report
21days ago
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX Get Rating) has earned an average rating of Moderate Buy from the six research firms that are currently covering the stock, Marketbeat reports. One analyst has rated the stock with a hold recommendation and four have given a buy ...
Business Wire
2 months ago
Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) today announced that Joshua Cohen and Justin Klee, Co-CEOs of Amylyx, will participate in the Evercore ISI 5th Annual HealthCONx Conference. The conference is being conducted in a virtual format, and the fireside chat will take place on Tuesday, November...
Ticker Report
2 months ago
Amylyx Pharmaceuticals (NASDAQ:AMLX Get Rating) had its target price upped by Citigroup to $51.00 in a research note published on Wednesday morning, Stock Target Advisor reports. Several other brokerages have also commented on AMLX. The Goldman Sachs Group increased their price target on ...
PR Newswire
3 months ago
NeuroSense Therapeutics Provides CEO's Q3 Update and Nasdaq Opening Bell Ceremony Remarks Video NeuroSense Therapeutics Provides CEO's Q3 Update and Nasdaq Opening Bell Ceremony Remarks Video PR Newswire CAMBRIDGE, Mass., Oct. 18, 2022 View the Nasdaq Opening Bell Ringing & CEO Message...
Frequently Asked Questions
Frequently Asked Questions
What is Amylyx Pharmaceuticals Inc share price today?
plus_minus_icon
Can Indians buy Amylyx Pharmaceuticals Inc shares?
plus_minus_icon
How can I buy Amylyx Pharmaceuticals Inc shares from India?
plus_minus_icon
Can Fractional shares of Amylyx Pharmaceuticals Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Amylyx Pharmaceuticals Inc stocks?
plus_minus_icon
What is today’s traded volume of Amylyx Pharmaceuticals Inc?
plus_minus_icon
What is today’s market capitalisation of Amylyx Pharmaceuticals Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Amylyx Pharmaceuticals Inc?
plus_minus_icon
What percentage is Amylyx Pharmaceuticals Inc down from its 52-Week High?
plus_minus_icon
What percentage is Amylyx Pharmaceuticals Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$0
$-1.57
(-3.99%)
logo-amlx
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00